Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Company Deals PIC

CellStore Signs Strategic Partnership Memorandum With Shanghai Cell Therapy Group – Deepening Cooperation in Cell Cryopreservation, Product Application Validation, and Industrial Synergy Across Cell and Gene Therapy

Fineline Cube Sep 10, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Deals

Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers

Fineline Cube Sep 10, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug

Eyenovia, Inc. Receives FDA Approval for Mydcombi, a First-of-Its-Kind Ophthalmic Spray

Fineline Cube May 9, 2023

US-based Eyenovia, Inc. (NASDAQ: EYEN) has announced obtaining market approval from the US Food and...

Drug Policy / Regulatory

NMPA Releases 67th Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube May 9, 2023

The National Medical Products Administration (NMPA) has released the 67th batch of reference drugs for...

Company Drug

Jiangsu Hengrui Pharmaceuticals Advances SHR-1819, SHR-2002, and Adebrelimab into New Clinical Trials

Fineline Cube May 9, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced receiving clinical trial approvals for its...

Company Drug

Ascletis Pharma Receives Approval for Phase IIa Study of ASC10 for RSV Infection

Fineline Cube May 9, 2023

China-based Ascletis Pharma Inc. (HKG: 1672) has announced receiving the green light to conduct a...

Company Deals

EQRx Inc. Abandons Plans for Low-Cost Drugs, Terminates Development of Three China-Sourced Products

Fineline Cube May 9, 2023

US-based biotech EQRx Inc., (Nasdaq: EQRX) has disclosed in its Q4 2022 financial report a...

Company Deals

Shunxi Holding Group Secures Licensing Deal for Cartherics’ CTH-004 in Greater China

Fineline Cube May 8, 2023

China-based Shunxi Holding Group Co. Ltd has entered into a licensing deal with Australia-based firm...

Company Drug

AstraZeneca’s MEK Inhibitor Koselugo Approved in China for Pediatric NF1-Related PN

Fineline Cube May 8, 2023

UK major AstraZeneca (AZ, NASDAQ: AZN) has announced that its mitogen-activated protein kinase (MEK) inhibitor,...

Company Deals

Shenzhen’s Angio8 Secures Tens of Millions in Series A Financing for Surgical Robot Development

Fineline Cube May 8, 2023

Angio8, a Shenzhen-based developer of vascular interventional surgical robots, has reportedly raised tens of millions...

Company Drug

BeiGene’s Brukinsa Receives NMPA Approval for Expanded Use in Leukemia and Lymphoma

Fineline Cube May 8, 2023

China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced that it has received approval...

Company Drug

Shanghai Junshi Biosciences’ Tuoyi Shows Promise in Phase III Study for ES-SCLC

Fineline Cube May 8, 2023

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced encouraging results from the...

Policy / Regulatory

Tianjin, Shandong, and Hainan Provinces Announce VBP Backup Suppliers for Round 8

Fineline Cube May 8, 2023

Tianjin, Shandong, and Hainan provinces in China have released their lists of backup suppliers following...

Company Drug

Suzhou GenAssist’s GEN6050 Receives US FDA Pre-IND Acceptance for Duchenne Muscular Dystrophy Treatment

Fineline Cube May 8, 2023

China-based Suzhou GenAssist Therapeutic Co., Ltd has announced that the US Food and Drug Administration...

Company Deals

Sinopharm Partners with Fudan University to Establish National Innovation Platform

Fineline Cube May 8, 2023

China National Pharmaceutical Group Corporation (Sinopharm, HKG: 1099) has announced a strategic partnership with Fudan...

Company Drug

Reistone Biopharma’s Edralbrutinib Earns Orphan Drug Designation for NMOSD from US FDA

Fineline Cube May 8, 2023

Reistone Biopharma Co., Ltd, a company incubated by Hengrui Medicine with an investment of USD...

Company Deals

Lingyi Biotechnology Secures RMB 100 Million in Series A Funding for Gene Therapy Pipeline

Fineline Cube May 6, 2023

China-based gene therapy developer Lingyi Biotechnology Co., Ltd has reportedly raised close to RMB 100...

Company Drug

Henlius Biotech’s HLX26 and HaiSiZhuang Combo for NSCLC Gets NMPA Phase II Approval

Fineline Cube May 6, 2023

Shanghai Henlius Biotech (HKG: 2696) has announced that it has received approval from the National...

Company Deals

Shanghai Junshi Biosciences Inks Exclusive License Deal with Dr. Reddy’s Laboratories for Tuoyi

Fineline Cube May 6, 2023

Shanghai Junshi Biosciences Co., Ltd (SHA: 688180), a China-based biotechnology firm, has announced an exclusive...

Company Deals

Sinopharm Partners with Shenzhen to Boost High-End Medical Device and Pharmaceutical Innovation

Fineline Cube May 6, 2023

China National Pharmaceutical Group Corporation (Sinopharm, HKG: 1099) has announced a strategic partnership with Shenzhen...

Company Deals

XtalPi Inc. and China Pharmaceutical University Launch Joint AI Research Center in China

Fineline Cube May 6, 2023

Sino-US artificial intelligence (AI) firm XtalPi Inc. has joined forces with China Pharmaceutical University (CPU)...

Company Medical Device

Omega Medical Imaging’s Soteria.AI Receives FDA Approval for Interventional Cardiology

Fineline Cube May 6, 2023

US-based medical technology firm Omega Medical Imaging has received marketing approval from the US Food...

Posts pagination

1 … 581 582 583 … 718

Recent updates

  • Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers
  • METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform
  • Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection
  • CSPC Wins NMPA Clinical Trial Approvals for Two Long‑Acting Injections – Weekly Rotigotine (SYH9087) for Parkinson’s Disease and World’s First Ready‑to‑Use Monthly Goserelin (SYH9102) for Solid Tumours
  • HBM Partner Solstice Oncology Launches with US$225 Million Series A Led by RA Capital – Advancing Second‑Generation CTLA‑4 Antibody Porustobart in Neoadjuvant Oncology
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers

Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Company Drug

CSPC Wins NMPA Clinical Trial Approvals for Two Long‑Acting Injections – Weekly Rotigotine (SYH9087) for Parkinson’s Disease and World’s First Ready‑to‑Use Monthly Goserelin (SYH9102) for Solid Tumours

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.